Skip to main content

Progressive Supranuclear Palsy clinical trials at UCSF

5 in progress, 3 open to eligible people

Showing trials for
  • Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)

    open to eligible people ages 18 years and up

    Prior research has identified profound sleep disruption in individuals with PSP. Not only were these individuals sleeping relatively short periods at night, they were also not recuperating lost sleep during the day. Research also showed the relative preservation of a series of nuclei key in regulating wake and arousal. Investigators believe that therapeutically targeting wake promoting centers with a specific medication will improve sleep quality and overall well-being in PSP. To study this, investigators will be doing a double blind, within subject, remote clinical trial with 3 conditions: suvorexant- which targets a wake promoting system, zolpidem- a standard hypnotic that engages sleep promoting systems, versus placebo. Each condition will last 1 week and will be separated by a 1 week washout period on no sleep medications. Investigators will measure sleep patterns and daytime symptoms to determine if suvorexant, zolpidem, or both medications are safe and effective for treating sleep disturbances and improving overall well-being in PSP.

    San Francisco, California

  • Trial of Parkinson's And Zoledronic Acid

    open to eligible people ages 60 years and up

    This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

    San Francisco, California and other locations

  • ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

    open to eligible people ages 18 years and up

    ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

    San Francisco, California and other locations

  • A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

    Sorry, in progress, not accepting new patients

    This is a Phase 2a study to assess the safety and tolerability of TPN-101 patients with PSP.

    San Francisco, California and other locations

  • Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

    Sorry, in progress, not accepting new patients

    A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients with the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome

    San Francisco, California

Our lead scientists for Progressive Supranuclear Palsy research studies include .

Last updated: